# 多模态 AI 驱动的癌症恶病质早期检测生物标志物

发布时间：2025年03月09日

`LLM应用`

> Multimodal AI-driven Biomarker for Early Detection of Cancer Cachexia

# 摘要

> 癌症恶病质是一种复杂的多因素综合征，表现为进行性肌肉消耗、代谢紊乱和系统性炎症，严重影响患者的生活质量和生存率。尽管研究者们进行了大量探索，但目前仍未找到单一的确诊生物标志物。因为与恶病质相关的指标，如血清标志物、肌肉测量和代谢异常，往往与其他疾病症状重叠，难以区分。现有的综合评估指标，包括癌症恶病质指数（CXI）、改良CXI（mCXI）和恶病质评分（CASCO），虽然整合了多种生物标志物，但缺乏统一的标准化阈值，限制了其临床应用价值。

本研究提出了一种基于多模态人工智能的新型生物标志物，旨在实现早期癌症恶病质的精准检测。该方案结合了开源大型语言模型（LLMs）与基于医学数据训练的基础模型，构建了一个创新的检测体系。通过整合患者的异质性数据，包括人口统计学信息、疾病状态、实验室检测结果、放射影像（CT扫描）和临床记录，采用了一种能够有效处理缺失数据的机器学习框架。与传统基于人工智能的模型（通常依赖于经过严格筛选的数据集进行训练）不同，本方法充分利用了临床环境中常规收集的数据，大大提升了其在真实世界中的应用价值。

此外，该模型还引入了置信度评估功能，能够智能识别需要进一步专家审查的复杂病例，确保临床解读的精准性。初步研究结果表明，通过多模态数据的整合，可以显著提高癌症诊断阶段恶病质的预测准确性。基于人工智能的生物标志物还能够根据患者的个性化特征（如年龄、种族、体重、癌症类型和分期）进行动态调整，克服了传统固定阈值生物标志物的局限性。这一多模态人工智能生物标志物为癌症恶病质的早期检测提供了一种可扩展且切实可行的临床解决方案，支持个性化干预策略的实施，有望显著改善患者的治疗效果和生存率。

> Cancer cachexia is a multifactorial syndrome characterized by progressive muscle wasting, metabolic dysfunction, and systemic inflammation, leading to reduced quality of life and increased mortality. Despite extensive research, no single definitive biomarker exists, as cachexia-related indicators such as serum biomarkers, skeletal muscle measurements, and metabolic abnormalities often overlap with other conditions. Existing composite indices, including the Cancer Cachexia Index (CXI), Modified CXI (mCXI), and Cachexia Score (CASCO), integrate multiple biomarkers but lack standardized thresholds, limiting their clinical utility. This study proposes a multimodal AI-based biomarker for early cancer cachexia detection, leveraging open-source large language models (LLMs) and foundation models trained on medical data. The approach integrates heterogeneous patient data, including demographics, disease status, lab reports, radiological imaging (CT scans), and clinical notes, using a machine learning framework that can handle missing data. Unlike previous AI-based models trained on curated datasets, this method utilizes routinely collected clinical data, enhancing real-world applicability. Additionally, the model incorporates confidence estimation, allowing the identification of cases requiring expert review for precise clinical interpretation. Preliminary findings demonstrate that integrating multiple data modalities improves cachexia prediction accuracy at the time of cancer diagnosis. The AI-based biomarker dynamically adapts to patient-specific factors such as age, race, ethnicity, weight, cancer type, and stage, avoiding the limitations of fixed-threshold biomarkers. This multimodal AI biomarker provides a scalable and clinically viable solution for early cancer cachexia detection, facilitating personalized interventions and potentially improving treatment outcomes and patient survival.

[Arxiv](https://arxiv.org/abs/2503.06797)